Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Aclaris Therapeutics	Cara Therapeutics	Arcutis Biotherapeutics	Theravance Biopharma	Shattuck Labs
Symbol	NASDAQ:ACRS	NASDAQ:CARA	NASDAQ:ARQT	NASDAQ:TBPH	NASDAQ:STTK
Price Information
Current Price	$21.19	$13.20	$25.75	$18.72	$26.79
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	0.8	1.8	1.6	1.6	1.5
Analysis Score	0.0	3.5	3.5	3.5	3.5
Community Score	2.6	3.1	2.2	2.4	3.5
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	1.7	1.7	1.7	0.0
Earnings & Valuation Score	0.6	0.6	0.6	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	N/A	$32.00	$54.67	$31.33	$45.60
% Upside from Price Target	N/A	142.42% upside	112.30% upside	67.38% upside	70.21% upside
Trade Information
Market Cap	$1.10 billion	$660.69 million	$1.29 billion	$1.22 billion	$1.12 billion
Beta	1.2	1.7	N/A	0.94	N/A
Average Volume	2,194,336	1,051,990	265,427	332,904	145,557
Sales & Book Value
Annual Revenue	$4.23 million	$19.89 million	N/A	$73.41 million	N/A
Price / Sales	261.03	33.22	N/A	16.65	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$1.69 per share	$4.66 per share	N/A	($3.94) per share	N/A
Price / Book	12.54	2.83	N/A	-4.75	N/A
Profitability
Net Income	$-161,350,000.00	$-106,370,000.00	$-42,000,000.00	$-236,460,000.00	N/A
EPS	($2.25)	($2.49)	($22.78)	($4.25)	N/A
Trailing P/E Ratio	N/A	N/A	N/A	N/A	0.00
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-941.07%	-360.35%	N/A	-345.16%	N/A
Return on Equity (ROE)	-104.00%	-64.36%	-81.74%	N/A	N/A
Return on Assets (ROA)	-64.47%	-53.22%	-57.72%	-51.60%	N/A
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.26%	N/A	N/A	N/A	N/A
Current Ratio	4.54%	8.00%	9.18%	4.32%	8.63%
Quick Ratio	4.54%	8.00%	9.18%	4.32%	8.63%
Ownership Information
Institutional Ownership Percentage	59.10%	67.01%	79.63%	80.41%	N/A
Insider Ownership Percentage	8.20%	5.70%	N/A	5.90%	N/A
Miscellaneous
Employees	57	80	54	359	59
Shares Outstanding	52.11 million	50.05 million	50.21 million	65.28 million	41.91 million
Next Earnings Date	8/6/2021 (Estimated)	8/9/2021 (Estimated)	8/10/2021 (Estimated)	8/5/2021 (Estimated)	8/9/2021 (Estimated)
Optionable	Optionable	Optionable	Not Optionable	Optionable	Not Optionable

Source	Headline
	Shattuck Labs Inc (STTK) CEO Taylor Schreiber Sold $1 million of Shares uk.finance.yahoo.com - May 13 at 4:39 AM
	Shattuck Labs, Inc. (NASDAQ:STTK) Director Josiah Hornblower Sells 8,227 Shares americanbankingnews.com - May 12 at 11:28 PM
	Shattuck Labs, Inc. (NASDAQ:STTK) CEO Sells $388,664.18 in Stock americanbankingnews.com - May 12 at 11:28 PM
	Shattuck Labs, Inc. (NASDAQ:STTK) Director Josiah Hornblower Sells 14,057 Shares americanbankingnews.com - May 12 at 11:28 PM
	Shattuck Labs, Inc. (NASDAQ:STTK) CEO Sells $220,912.24 in Stock americanbankingnews.com - May 12 at 11:28 PM
	Shattuck Labs (NASDAQ:STTK) Stock Price Down 5.6% americanbankingnews.com - May 12 at 12:38 PM
	Shattuck Labs (NASDAQ:STTK) Releases Quarterly Earnings Results americanbankingnews.com - May 11 at 1:38 PM
	What Percentage Of Shattuck Labs, Inc. (NASDAQ:STTK) Shares Do Insiders Own? nasdaq.com - May 11 at 12:38 AM
	Shattuck Labs Reports First Quarter 2021 Financial Results and Recent Business Highlights finance.yahoo.com - May 10 at 9:36 AM
	Shattuck Labs (NASDAQ:STTK) Trading Down 7% americanbankingnews.com - May 5 at 1:15 PM
	Shattuck Labs (NASDAQ:STTK) Shares Gap Down Following Insider Selling americanbankingnews.com - May 3 at 10:34 AM
	Insider Selling: Shattuck Labs, Inc. (NASDAQ:STTK) CFO Sells 20,000 Shares of Stock americanbankingnews.com - May 3 at 4:48 AM
	Shattuck Labs Announces Participation in Upcoming May Conferences finance.yahoo.com - April 30 at 6:30 PM
	Shattuck Labs Announces Participation in the 7th Annual Truist Securities Life Sciences Summit finance.yahoo.com - April 28 at 5:45 PM
	Shattuck Labs (NASDAQ:STTK) Sees Large Volume Increase americanbankingnews.com - April 27 at 11:38 AM
	Shattuck Labs (NASDAQ:STTK) Trading Up 8.9% americanbankingnews.com - April 26 at 3:40 PM
	Shattuck Labs Poised To Bounce Back Strongly This Year finance.yahoo.com - April 26 at 1:13 PM
	Shattuck Labs (NASDAQ:STTK) Now Covered by Berenberg Bank americanbankingnews.com - April 20 at 9:02 AM
	Shattuck Labs (NASDAQ:STTK) Receives New Coverage from Analysts at Berenberg Bank marketbeat.com - April 20 at 8:26 AM
	Erin Ator Thomson Sells 7,000 Shares of Shattuck Labs, Inc. (NASDAQ:STTK) Stock americanbankingnews.com - April 19 at 8:18 PM
	Shattuck Labs, Inc. (NASDAQ:STTK) CFO Andrew R. Neill Sells 24,000 Shares americanbankingnews.com - April 19 at 7:34 PM
	Could The Shattuck Labs, Inc. (NASDAQ:STTK) Ownership Structure Tell Us Something Useful? finance.yahoo.com - April 12 at 7:46 PM
	Shattuck Labs Highlights Preclinical Data for SL-9258 (TIGIT-Fc-LIGHT) in an Acquired Resistance Model and Expanded Preclinical Data from the GADLEN™ Platform at AACR 2021 finance.yahoo.com - April 12 at 8:23 AM
	Shattuck Labs Announces Participation in Needham’s 20th Annual Healthcare Conference finance.yahoo.com - April 6 at 8:45 AM
	Shattuck Labs Posts Narrower-Than-Estimated 4Q Loss finance.yahoo.com - March 16 at 12:56 PM
	Shattuck Labs Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights feeds.benzinga.com - March 15 at 5:10 PM

Date	Company	Brokerage	Action
4/27/2021	Aclaris Therapeutics	HC Wainwright	Initiated Coverage
1/2/2020	Aclaris Therapeutics	SVB Leerink	Reiterated Rating
10/11/2019	Aclaris Therapeutics	William Blair	Reiterated Rating
9/6/2019	Aclaris Therapeutics	JMP Securities	Downgrade
8/9/2019	Aclaris Therapeutics	Cantor Fitzgerald	Reiterated Rating
5/5/2021	Cara Therapeutics	Needham & Company LLC	Lower Price Target
9/8/2020	Cara Therapeutics	Canaccord Genuity	Reiterated Rating
7/30/2019	Cara Therapeutics	Piper Jaffray Companies	Boost Price Target
5/29/2019	Cara Therapeutics	Laidlaw	Boost Price Target
2/6/2019	Cara Therapeutics	Jefferies Financial Group	Initiated Coverage
1/15/2019	Cara Therapeutics	Bank of America	Initiated Coverage
2/2/2021	Arcutis Biotherapeutics	Truist	Boost Price Target
2/1/2021	Arcutis Biotherapeutics	Cowen	Boost Price Target
1/28/2021	Arcutis Biotherapeutics	Jonestrading	Initiated Coverage
11/9/2020	Arcutis Biotherapeutics	The Goldman Sachs Group	Upgrade
2/25/2020	Arcutis Biotherapeutics	Guggenheim	Initiated Coverage
5/13/2021	Theravance Biopharma	Morgan Stanley	Lower Price Target
11/23/2020	Theravance Biopharma	Evercore ISI	Reiterated Rating
8/7/2020	Theravance Biopharma	Piper Sandler	Lower Price Target
7/7/2020	Theravance Biopharma	JPMorgan Chase & Co.	Initiated Coverage
4/20/2021	Shattuck Labs	Berenberg Bank	Initiated Coverage
1/20/2021	Shattuck Labs	Citigroup	Boost Price Target
11/3/2020	Shattuck Labs	Smith Barney Citigroup	Initiated Coverage
11/3/2020	Shattuck Labs	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Initiated Coverage

(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources